Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob W J Collin

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|December 1, 2017
Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal DystrophiesAlejandro Garanto, Rob W J Collin
Current Opinion in Ophthalmology|February 3, 2017
Applications of antisense oligonucleotides for the treatment of inherited retinal diseasesRob W J Collin, Alejandro Garanto
Genes|February 9, 2020
Preface of Special Issue "Molecular Therapies for Inherited Retinal Diseases"Rob W J Collin, Alejandro Garanto
Molecular and Cellular Neurosciences|September 13, 2005
The amyloid-beta precursor-like protein APLP2 and its relative APP are differentially regulated during neuroendocrine cell activationRob W J Collin, Gerard J M Martens
Brain Research|April 22, 2006
The coding sequence of amyloid-beta precursor protein APP contains a neural-specific promoter elementRob W J Collin, Gerard J M Martens
International Journal of Molecular Sciences|March 12, 2015
Species-dependent splice recognition of a cryptic exon resulting from a recurrent intronic CEP290 mutation that causes congenital blindnessAlejandro Garanto, Lonneke Duijkers, Rob W J Collin
Molecular Aspects of Medicine|October 2, 2025
Antisense oligonucleotides for inherited retinal diseases: a comprehensive reviewHossein D Banadaki, Alejandro Garanto, Rob W J Collin
Genes|August 31, 2019
Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and ChallengesIrene Vázquez-Domínguez, Alejandro Garanto, Rob W J Collin
Nucleic Acid Therapeutics|March 11, 2024
Understanding and Rescuing the Splicing Defect Caused by the Frequent <i>ABCA4</i> Variant c.4253+43G>A Underlying Stargardt DiseaseNuria Suárez-Herrera, Alejandro Garanto, Rob W J Collin
Advances in Experimental Medicine and Biology|October 3, 2015
Antisense Oligonucleotide Therapy for Inherited Retinal DystrophiesXavier Gerard, Alejandro Garanto, Jean-Michel Rozet, et al.
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Methods in Molecular Biology (Clifton, N.J.)|December 1, 2017
Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal DystrophiesAlejandro Garanto, Rob W J Collin
Current Opinion in Ophthalmology|February 3, 2017
Applications of antisense oligonucleotides for the treatment of inherited retinal diseasesRob W J Collin, Alejandro Garanto
Genes|February 9, 2020
Preface of Special Issue "Molecular Therapies for Inherited Retinal Diseases"Rob W J Collin, Alejandro Garanto
Molecular and Cellular Neurosciences|September 13, 2005
The amyloid-beta precursor-like protein APLP2 and its relative APP are differentially regulated during neuroendocrine cell activationRob W J Collin, Gerard J M Martens
Brain Research|April 22, 2006
The coding sequence of amyloid-beta precursor protein APP contains a neural-specific promoter elementRob W J Collin, Gerard J M Martens
International Journal of Molecular Sciences|March 12, 2015
Species-dependent splice recognition of a cryptic exon resulting from a recurrent intronic CEP290 mutation that causes congenital blindnessAlejandro Garanto, Lonneke Duijkers, Rob W J Collin
Molecular Aspects of Medicine|October 2, 2025
Antisense oligonucleotides for inherited retinal diseases: a comprehensive reviewHossein D Banadaki, Alejandro Garanto, Rob W J Collin
Genes|August 31, 2019
Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and ChallengesIrene Vázquez-Domínguez, Alejandro Garanto, Rob W J Collin
Nucleic Acid Therapeutics|March 11, 2024
Understanding and Rescuing the Splicing Defect Caused by the Frequent <i>ABCA4</i> Variant c.4253+43G>A Underlying Stargardt DiseaseNuria Suárez-Herrera, Alejandro Garanto, Rob W J Collin
Advances in Experimental Medicine and Biology|October 3, 2015
Antisense Oligonucleotide Therapy for Inherited Retinal DystrophiesXavier Gerard, Alejandro Garanto, Jean-Michel Rozet, et al.
Pageof 15